HDL, Atherosclerosis, and Emerging Therapies
نویسندگان
چکیده
منابع مشابه
HDL, Atherosclerosis, and Emerging Therapies
This review aims to provide an overview on the properties of high-density lipoproteins (HDLs) and their cardioprotective effects. Emergent HDL therapies will be presented in the context of the current understanding of HDL function, metabolism, and protective antiatherosclerotic properties. The epidemiological association between levels of HDL-C or its major apolipoprotein (apoA-I) is strong, gr...
متن کاملEmerging Therapies for Atherosclerosis
In the United States alone, about 250,000 people develop significant mitral regurgitation (MR) each year, with almost 50,000 undergoing surgery. Surgical repair of a diseased mitral valve has become the treatment of choice for patients with significant MR. Since there is no single therapeutic approach for every etiology of MR, surgical mitral valve repair includes a variety of techniques that a...
متن کاملEmerging Drug Therapies for Heart Failure
Heart failure is associated with high morbidity and mortality and is proving to be an economic burden in developing countries. A number of therapeutic agents are presently employed in heart failure; but they are not sufficient to control symptoms of heart failure. Moreover, the prevalence of chronic heart failure is progressively increasing and thus there is a continuing need to develop effecti...
متن کاملHIV Therapies and Atherosclerosis
The widespread use of nucleoside analog reverse transcriptase inhibitors (NRTIs) and HIV protease inhibitors (PIs) in Western countries has substantially reduced morbidity and mortality in patients with HIV infection. Concomitantly, however, adverse effects associated with long-term use of these agents are becoming recognized. A growing body of literature suggests that many adverse effects asso...
متن کاملEmerging therapies.
The results of the European Cooperative Acute Stroke Study III (ECASS III) provide an important advance for the field of acute stroke therapy. The study was well-designed and conducted. The trial provides unequivocal and straightforward evidence that treatment with intravenous (IV) tissue plasminogen activator (tPA) initiated 3 to 4.5 hours after the onset of ischemic stroke improves 90-day out...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cholesterol
سال: 2013
ISSN: 2090-1283,2090-1291
DOI: 10.1155/2013/891403